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Patients with UICC stage II colorectal cancer (CRC) have a risk of approximately 20% to develop disease recurrence after tumour
resection. The presence and significance of micrometastases for locoregional recurrence in these patients lacking histopathological
lymph node involvement on routine stained HE sections is undefined. Oestrogen receptor (ER) promoter methylation has earlier
been identified in CRC. Therefore, we evaluated the methylation status of the ER promoter in lymph nodes from 49 patients with
CRC UICC stage I and II as a molecular marker of micrometastases and predictor of local recurrence. DNA from 574 paraffin-
embedded lymph nodes was isolated and treated with bisulphite. For the detection of methylated ER promoter sequences,
quantitative real-time methylation-specific PCR was used. Of the 49 patients tested, 15 (31%) had ER methylation-positive lymph
nodes. Thirteen of those (86%) remained disease free and two (14%) developed local recurrence. In the resected lymph nodes of 34
of the 49 patients (69%), no ER promoter methylation could be detected and none of these patients experienced a local relapse. The
methylation status of the ER promoter in lymph nodes of UICC stage I and II CRC patients may be a useful marker for the
identification of patients at a high risk for local recurrence.
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Colorectal cancer (CRC) is the third most common cancer in
western countries with an incidence of 45–60 per 100000 per year
in Europe and the United States (Landis et al, 1998). In CRC, the
histopathological lymph node status at the time of surgery is one of
the main prognostic factors. Adjuvant chemotherapy has been
shown to improve disease-free survival by 20–30% in patients
after curative resection for colon cancer metastatic to regional
lymph nodes (UICC stage III; Dukes C). In contrast, in UICC stage
II disease (T3–4, N0, M0; Dukes stage B), only a minimal survival
benefit can be achieved with adjuvant chemotherapy. Therefore,
patients with UICC stage II CRC are treated with adjuvant
chemotherapy only in the presence of additional negative
prognostic factors indicating a high risk for relapse (e.g.
undifferentiated tumours, tumour perforation). However, approxi-
mately 20% of the UICC stage II patients develop local recurrence
or distant metastases and would potentially benefit from adjuvant
chemotherapy. At present, these patients cannot be identified at
the time of surgery.
The presence and prognostic relevance of lymph node micro-
metastases in CRC patients without routine histopathological
evidence of lymph node involvement by standard criteria is
unclear. Several molecular markers including CEA, CK, MUC2 and
p53 have been used to detect micrometastases in regional lymph
nodes. However, to date, these markers investigated are unreliable
due to low sensitivity and/or low specificity (Sanchez-Cespedes
et al, 1999; Noura et al, 2002b; Rosenberg et al, 2002; Ho et al,
2004; Lee et al, 2006). Depending on the respective marker and
method used, micrometastases were detected in 20–100% of
resected histologically negative lymph nodes of CRC patients with
varying results regarding their prognostic value (Futamura et al,
1998). This wide range of positive results for micrometastases in
resected lymph nodes is clearly influenced by differences in the
specificity and sensitivity of the candidate markers and detection
methods used. In addition, it raises the question of the clinical
significance of single tumour cells for disease recurrence.
Issa et al (1994) first described the methylation of CpG (cytosine
phospho guanine) islands in the promoter of the oestrogen
receptor (ER) in CRC. Non-malignant tissues from thyroid, breast,
lung, cervix and prostate were examined for the presence of ER
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spromoter methylation and found to be negative (Esteller et al,
2001). In contrast, ER promoter methylation seems to play a role in
the early steps of carcinogenesis in several tumour sites including
lymphoma, oesophageal cancer and CRC (Issa et al, 1994, 1996;
Eads et al, 2000), being present in almost 100% of primary
colorectal tumours. In addition to its potential role in colon
carcinogenesis, CpG island methylation of the ER promoter might
therefore be a useful marker for molecular detection of micro-
metastases in lymph nodes of CRC patients.
In addition to micrometastases, genetic subtypes or distinct
molecular signatures of the primary tumour have been linked to
the probability of local recurrence (Lenz et al, 1998; Gryfe et al,
2000; Kim et al, 2007). Kim et al (2007) showed a higher
recurrence-free survival for patients with microsatellite-instable
(MSIþ) tumours and Gryfe et al (2000) could show that MSIþ
tumours have a decreased likelihood of metastasising to regional
lymph nodes. Other molecular markers such as p53 overexpression
and thymidylate synthase have also been linked to higher
recurrence rates (Lenz et al, 1998). Except for one report,
promoter methylation other than hMLH1 and hMSH2, which then
leads to MSI, has not been linked to disease recurrence (de Maat
et al, 2008). MSIþ tumours are more frequent in the right colon
(Kim et al, 2007) and define one subtype of CRC (Jass, 2007).
Nevertheless, ER promoter methylation is more frequent in the left
colon and rectum at least in normal tissue independent of the
location of CRC (Issa et al, 1994).
During surgical resection of CRC, draining lymph nodes are
removed together with the primary tumour. The number of
metastatic lymph nodes, and also the absolute number of resected
lymph nodes or as shown in recent reports the lymph node ratio of
metastatic to non-metastatic lymph nodes, predicts the likelihood
of disease recurrence in CRC stage III patients. This might be
explained by the fact that resected metastatic lymph nodes drain
into lymph node areas, which are not resected by the surgeon
(Yagci et al, 2007). As micrometastases are thought to cause local
recurrence through this route, the detection of micrometastases by
real-time methylation-specific PCR (rt-MSP) in resected lymph
nodes could be a tool to predict local disease recurrence caused by
single tumour cells remaining outside the resected area.
Therefore, the aim of this study was to define the value of ER
promoter methylation, detected by rt-MSP in resected lymph
nodes from patients with CRC UICC stage I and II, as a predictor
of local disease recurrence.
MATERIALS AND METHODS
Study population
A total of 76 patients were examined in this study (Figure 1). As
positive control, primary tumours and microscopically proven
metastatic lymph nodes from 14 patients with CRC UICC stage III
disease (any T, N1–2, M0) were analysed. As negative control,
served lymph nodes from 12 patients obtained from colon
resection for non-neoplastic diseases, for example ileus and
ulcerative colitis. Fifty consecutive patients with CRC UICC stage
I or II disease underwent complete tumour resection at the
Department of General and Visceral Surgery at the University
Medical Center Freiburg, Germany, between January 2000 and
December 2002. One patient was lost to follow-up, therefore 49
patients were analysed for the presence of micrometastases. The
latter only included patients with completely (R0) resected
sporadic CRC, and histopathologically classified pN0 (negative)
lymph nodes were analysed in this retrospective study. The
patients with rectal cancer did not have neoadjuvant therapy.
Microsatellite status was assessed earlier in 27 of these 49 primary
CRCs (Gerlach et al, 2006). In all, 7 out of 27 (26%) of the cases
were MSI positive and 20 out of 27 (74%) were MSI negative.
Lymph node processing and DNA extraction
Serial sections of surgically resected lymph nodes were analysed
after having been completely processed by formalin fixation,
paraffin embedding and routine diagnostics of histopathological
TNM classification, for the presence of micrometastases by
rt-MSP. In total, 574 lymph nodes (mean 9.8 per patient, range
1–29) were available for analysis. Case-specific clinicopathological
and experimental parameters, including the number of lymph
nodes analysed by rt-MSP and clinical follow-up, are given in
Table 2.
Six serial sections were used for DNA isolation (6 10mm) and
one section (3mm) for HE staining. The lymph nodes were
manually microdissected and pooled for DNA isolation to yield
one sample per patient. Tissue sections were deparaffinised in
xylene and rehydrated using ethanol in decreasing concentrations.
Rehydrated tissue sections were digested using proteinase K
dissolved in TE buffer diluted at 1:10 in distilled water. Genomic
DNA was isolated using a commercially available DNA extraction
kit (DNeasy
s; Qiagen, Hilden, Germany). The DNA concentration
of each patient sample was measured (Nanodrop
s; PeqLab,
Erlangen, Germany) with a mean concentration of 157ngml
 1
(±82ngml
 1). Two micrograms of each DNA sample were treated
with sodium bisulphite converting unmethylated cytosine to uracil
and leaving methylated cytosine intact, as described by Herman
et al (1996). After bisulphite modification, the DNA was purified
and eluted in 20mlH 2O.
ER promoter analysis
To define the most suitable methylated ER promoter region, we
first established a conventional MSP. Lapidus et al (1998) divided
the CpG island of the ER promoter into six regions (ER1–ER6)
and tested them for methylation and its functional relevance
regarding gene expression in breast cancer cell lines. Comparison
of the different primer sets showed the region ER4 of the CpG
island to be most specific. This region was identical to the region
analysed by Issa et al (1994) for its functional relevance. The
primer and probe of the more sensitive rt-MSP used to analyse the
study population as well as the positive and negative control group
also cover this region and were published recently (Eads et al,
2000). Overall, the primer sequences used are as follows:
MSP forward primer, 50-cgagctggagcccctgaaccgtcc-30 and MSP
reverse primer, 50-cggccgccgccaacgcgcag-30. For rt-MSP, the
following oligonucleotides were used: forward primer, 50-gg
cgttcgttttgggattg-30; reverse primer, 50-gccgacacgcgaactctaa-30;
76 patients 
total study cohort 
14 patients with
UICC stage III CRC 
Positive control 
12 patients with non-
neoplastic disease. 
Negative control 
50 patients with 
UICC stage I/II CRC 
were resected 
49 patients with
UICC stage I/II 
CRC analyzed for 
micrometastases 
One patient lost to
follow-up 
Figure 1 The whole study population comprised 76 patients. Fourteen
patients were in the positive and 12 in the negative control group. Fifty
patients had been resected for stage I or II CRC. As one patient was lost to
follow-up, 49 patients were analysed by ER promoter rt-MSP.
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sTaqMan
s probe, FAM 50-cgataaaaccgaacgacccgacga-30 TAMRA.
PCR primers were obtained by Genescan (Freiburg, Germany). The
probe was custom synthesised by Applied Biosystems (Foster City,
CA, USA). Concentrations were 9mM for the forward, 3mM for the
reverse primer and 2.5mM for the probe.
Two microlitres of the eluate containing the bisulphite-treated
DNA has been used for each rt-MSP. Amplifications were carried
out in 96-well plates in a 7000 Sequence detector (Applied
Biosystems) in triplets using Universal Mastermix
s (Applied
Biosystems). The reaction volume was 25ml. Thermal cycling was
initiated by denaturation at 951C for 10min. The PCR profile
was 951C for 15s and 601C for 1min for a total of 50 cycles. Each
plate contained patient samples and multiple water blanks as well
as positive (MDA-MB-435 and MDA-MB-231 cell lines) and
negative controls (MCF-7 cell line). The cell lines used have been
well characterised regarding the methylation status of their ER
promoter (Lapidus et al, 1998). Serial dilutions of the positive
control DNA were used to generate a calibration curve for each
analysis. To determine the relative levels of methylated ER
promoter DNA in each sample, the values of ER promoter
methylation were compared with the values of the internal
reference, the housekeeping gene ACTB. Dilution series showed
linearity of amplification down to 1:10000 for rt-MSP for
methylated ER promoter as well as for ACTB.
RESULTS
To validate our approach and to confirm the findings by Issa et al
(1994), we first examined primary invasive CRCs and lymph nodes
with histologically proven metastasis from 14 patients with UICC
stage III (any pT, pN1–2, M0) CRC. In 14 out of 14 (100%) CRC
and in 13 out of 14 (93%) histologically positive lymph nodes, an
aberrantly methylated ER promoter sequence was detected. None
of the lymph nodes of the negative control group (0 out of 12),
resected for non-neoplastic bowel disease (obstruction or ulcera-
tive colitis), showed methylation of the ER promoter. Next, lymph
nodes from 49 patients with UICC stage I or II CRC were analysed
(Tables 1 and 2). The mean age of the patient population was 67
years (range 36–90), 25 patients were women and 24 men. Eleven
patients had UICC stage I disease corresponding to TNM category
pT2pN0 and 38 patients had UICC stage II with pT3pN0 (n¼37)
and pT4pN0 (n¼1) tumours, respectively. In all, 9 (18%) patients
had cancer of the rectum, 12 (24%) of the sigmoid colon, 7 (14%)
of the transverse and descending and 21 (43%) of the ascending
colon, respectively. At the last follow-up as of December 2006, the
average follow-up was 64 months (range 47–79). Two patients
with rectal cancer had received adjuvant radiochemotherapy.
Ten of 49 patients died during the follow-up period, three from
disease recurrence, one from an accident and six from cardio-
vascular disease. In total, four patients developed recurrence
(overall recurrence rate 8.2%). One patient developed local and
distant recurrence, one patient developed solely local recurrence
and two patients developed solely distant metastases. Patients who
died and did not develop tumour recurrence were treated as
censored by statistical survival analysis.
Both patients with local recurrence were positive by rt-MSP
(sensitivity 100%, positive predictive value 13.3%). They had well
and moderately differentiated tumours of the rectum and sigmoid,
respectively, and both had been staged as pT3 pN0 cM0 (UICC
stage II). In both patients with local recurrence, six and seven
lymph nodes had been examined. Local recurrence was diagnosed
11 and 33 months after initial diagnosis. Both patients died of their
tumour recurrence.
Of the 49 patients tested, 15 (31%) had ER methylation-positive
lymph nodes. Thirteen of those (86%) remained disease free and
two (14%) developed local recurrence. In the resected lymph nodes
of 34 of the 49 patients (69%), no ER promoter methylation could
be detected and none of these patients experienced a local relapse.
Of the 13 patients with positive ER promoter methylation in their
resected lymph nodes and a disease-free follow-up, three had CRC
UICC stage I and 10 UICC stage II. Regarding age, gender, tumour
localisation, UICC stage, grading and the number of resected
lymph nodes, there were no statistically significant differences
between the patients with and without positive lymph nodes
detected by ER promoter methylation.
None of the rt-MSP-negative patients (0 out of 34) developed
local recurrence (specificity 72.3%, negative predictive value
100%), but 2 out of 34 (6%) rt-MSP-negative patients developed
metastases in the liver and lung without evidence for lymph node
or local recurrence. In these patients there was no methylation of
the ER promoter in the lymph nodes removed at surgery. In 27 out
of the 49 patients with CRC UICC stage I/II, MSI status, as
previously assessed (Gerlach et al, 2006), was correlated with
rt-MSP results and other clinical variables (Table 2); 7 out of 27
patients were MSIþ. There was no statistical correlation between
microsatellite status, rt-MSP results and local or distant recurrence
or any other clinical variables.
DISCUSSION
According to clinical staging systems (UICC, Dukes and Astler-
Coller), the presence of lymph node metastases at the time of
diagnosis predicts a poor prognosis for CRC patients. But even
among patients with lymph nodes negative by histopathologic
criteria (pN0), 10–20% will develop local tumour recurrence,
which has been attributed to micrometastases outside the resected
lymphatic drainage area. The most sensitive methods to detect
micrometastases are immunohistochemistry (IHC) and nucleic
acid-based methods. Only few studies could show micrometastases
detected by IHC in lymph nodes of UICC stage I and II patients to
correlate with disease recurrence and survival (Noura et al,
Table 1 Summary of patient characteristics
Patient characteristic n¼49
Age mean (range) 67 range 36–90
Male 24 49%
Female 25 51%
UICC stage
I 11 22%
II 38 78%
pT category
pT2 11 22%
pT3 37 76%
pT4 1 2%
Grading
Well differentiated 3 6%
Moderately differentiated 43 88%
Poorly differentiated 3 6%
Tumour site
Ascending colon 21 43%
Transverse colon 4 8%
Descending colon 3 6%
Sigmoid colon 12 24%
Rectum 9 18%
MSI status
Positive 7 26%
Negative 20 74%
MSI¼microsatellite instability; UICC¼International Union Against Cancer.
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s2002a,b; Lee et al, 2006; Messerini et al, 2006). These conflicting
data may be due to the specificity and sensitivity of proteins used
for detection as well as the variable thickness and number of tissue
sections analysed (Nordgard et al, 2003). Therefore, we did not
compare the results of rt-MSP with IHC studies.
In addition, there have been several reports on the detection of
CK mRNA by RT–PCR. Some studies showed a correlation
between CK 20 expression detected by RT–PCR and disease
recurrence as well as overall survival, whereas other studies did not
(Ichikawa et al, 1998; Liefers et al, 1998; Sanchez-Cespedes et al,
1999; Bernini et al, 2000; Miyake et al, 2001; Noura et al, 2002a,b;
Merrie et al, 2003; Ho et al, 2004; Lassmann et al, 2004; Pellise
et al, 2004; Lee et al, 2006). As CK expression is also found in
granulocytes and normal blood cells, the highly sensitive RT–PCR
may produce false-positive results as described by Bostick et al
(1998), Jung et al (1999) and Bustin et al (2000). This hypothesis
is supported by a report by Rosenberg et al (2002), who found
CK-positive cells on histological examination exclusively on the
outside of lymph nodes in almost 30% of RT–PCR-positive
specimens. Other markers, including CEA, MUC2, GCC,
matrilysin, b-HCG and others, have been explored to detect lymph
node micrometastases by RT–PCR and yielded inconsistent results
(Ichikawa et al, 1998; Cagir et al, 1999; Bernini et al, 2000).
Expression levels of these different markers can vary considerably
among tumour specimens of the same entity. Therefore, these
markers have to be compared with the primary tumour (Hanski
et al, 1997; Waldman et al, 1998). In contrast, the ER promoter
methylation is present in almost 100% of CRC. Also, in our
population, all primary CRCs were positive for ER promoter
methylation. Next, we were able to show ER promoter methylation
Table 2 Case-specific clinicopathological parameters and experimental data on the number of investigated lymph nodes and corresponding rt-MSP results
(n¼49)
Patient pT category Grading MSI+ Recurrence Number of investigated lymph nodes rt-MSP
1 3 2 Yes No 11  
23 2 N o N o 1 8 +
33 2 N o N o 2 9 +
4 3 2 No Local 6 +
53 2 N D N o 2 4  
62 2 N o N o 5  
73 2 N D N o 7  
8 3 2 No Distant 14  
93 2 N D N o 5  
10 2 1 ND No 9  
11 3 2 No No 5 +
12 2 2 Yes No 9  
13 3 2 No No 4  
14 2 2 No No 11  
15 3 3 No No 16  
16 3 2 ND No 4  
17 4 2 Yes No 17 +
18 3 2 ND No 1  
19 3 2 ND No 3  
20 3 2 No No 10  
21 3 2 ND No 7  
22 3 2 No No 9  
23 2 2 Yes Distant 4  
24 3 2 ND No 2  
25 2 2 ND No 2  
26 3 2 No No 5 +
27 3 2 ND No 4  
28 2 2 Yes No 19 +
29 3 2 ND No 7  
30 3 2 ND No 4 +
31 3 1 Yes Local and distant 7 +
32 3 2 ND No 5  
33 3 2 No No 5 +
34 3 3 No No 7 +
35 2 2 No No 10 +
36 3 2 Yes No 17  
37 3 2 No No 14  
38 3 1 No No 6 +
39 3 2 ND No 21  
40 3 2 ND No 12  
41 3 2 ND No 18  
42 3 2 No No 6  
43 2 3 ND No 13  
44 2 2 No No 9 +
45 3 2 ND No 5  
46 2 2 ND No 16  
47 2 2 ND No 22  
48 3 2 ND No 14  
49 3 2 No No 9 +
MSI+¼microsatellite instability; ND¼not determined; rt-MSP¼real-time methylation-specific PCR.
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sas a good marker of lymph node metastases. To use this marker for
the detection of micrometastases we analysed lymph nodes from a
study population with UICC stage I and II CRCs. Instead of
expression levels here we detected gene promoter methylation by
PCR-based methods. The high stability of DNA compared with
RNA is one of the main advantages of DNA-based detection
methods, which therefore can be applied to the analysis of
paraffin-embedded tissues. We demonstrated rt-MSP of DNA from
paraffin-embedded lymph node tissue as a robust and practicable
method to detect micrometastases.
The high stability of DNA compared with RNA is one of the
main advantages of DNA-based detection methods, which there-
fore can be applied to the analysis of paraffin-embedded tissues.
We demonstrated rt-MSP of DNA from paraffin-embedded lymph
node tissue as a robust and practicable method to detect
micrometastases.
The high negative predictive value was achieved, because none
of the 33 patients negative for ER promoter methylation in their
lymph nodes developed local recurrence. On the other hand, not
all MSP-positive patients developed local recurrence during follow-
up. This limitation might in part be explained by a too short
follow-up period, the heterogeneity of the study population in
terms of the number of investigated lymph nodes or other
molecular factors, respectively. The small number of recurrences is
another limitation that does not allow a statistical multivariable
analysis and results in a low positive predictive value.
Molecular factors have recently been shown to predict disease
outcome as distinct genetic subtypes of CRC are defined (Shen
et al, 2007). Especially, MSI status has been correlated with
recurrence and prognosis of CRC (Gryfe et al, 2000; Kim et al,
2007). Therefore, we compared the MSI status of primary tumours
in a subset of patients with the presence of ER promoter
methylation in lymph nodes and disease recurrence. Of 27
patients, seven were MSIþ, but showed no clear-cut trend for
rt-MST results and disease recurrence. On account of the small
number of recurrences and the limited statistical significance we
did not compare molecular variables other than MSI.
Another reason for the high rate of detected micrometastases by
rt-MSP compared with recurrences might be the high sensitivity of
rt-MSP, which may detect single tumour cells in a lymph node that
might not have the potential to develop to a clinically relevant
tumour. This obviously raises the question of the clinical
significance of micrometastases for the individual patient.
However, the most likely explanation for the lower positive
predictive value seems to lie in a potentially complete resection of
all micrometastases bearing lymph nodes at surgery.
Lymph node and distant metastases represent two different
routes of CRC progression. Whereas the first is probably due to a
spread of tumour cells through the local lymph system, the latter
arises from circulating tumour cells. Histopathological lymph node
involvement is a predictor of disease recurrence. Generally, the
route of tumour spread is dependant on the overall tumour load.
This interpretation is supported by the close correlation between
the quantitative level of CEA transcripts in serum and tumour
stage (Ho et al, 2004; Ohlsson et al, 2006). For local recurrence, ER
promoter methylation in lymph nodes could narrow down the
patients at risk but not for distant metastases. Overall, the
correlation of micrometastatic lymph node involvement together
with tumour DNA in plasma from CRC patients may better assess
the overall risk of disease recurrence.
In summary, rt-MSP for ER promoter methylation may
represent a sensitive and robust method to identify patients with
UICC stage I and II CRC at risk for local recurrence. Positive
patients have a risk for local recurrence similar to UICC stage III.
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